Condition: Non Small Cell Lung Cancer · Sponsor: N-Power Medicine
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
This description comes directly from the study's public registry record.
N-Power Medicine Support · 1-833-467-6734 · support@npowermedicine.com
Always discuss trial participation with your own doctor first.
| Pacific Cancer Care | Monterey, California, United States | Recruiting |
| Torrance Memorial Physician Network-Cancer Care | Torrance, California, United States | Recruiting |
| John Muir Health | Walnut Creek, California, United States | Recruiting |
| Bayhealth Cancer Center- Kent | Dover, Delaware, United States | Recruiting |
| Bayhealth Cancer Center- Sussex | Milford, Delaware, United States | Recruiting |
| Kootenai Clinic Cancer Services Coeur d'Alene | Coeur d'Alene, Idaho, United States | Recruiting |
| Northwest Oncology & Hematology | Elk Grove Village, Illinois, United States | Recruiting |
| Lankenau Medical Center | Paoli, Pennsylvania, United States | Not Yet Recruiting |
| Oncology Consultants, P.A. | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07028489